MeiraGTx Holdings plc(MGTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | RUT | P/E | 13.45 | EPS (ttm) | 0.71 | Insider Own | 23.34% | Shs Outstand | 94.2M | Perf Week | 3.04% |
| Market Cap | 0.91B | Forward P/E | - | EPS next Y | -683.81% | Insider Trans | -1.28% | Shs Float | 73.6M | Perf Month | -10.98% |
| Enterprise Value | 0.88B | PEG | - | EPS next Q | -0.5 | Inst Own | 63.27% | Short Float | 8.74% | Perf Quarter | -20.12% |
| Income | 0.08B | P/S | 2.29 | EPS this Y | 121.13% | Inst Trans | 12.97% | Short Ratio | 8.04 | Perf Half Y | 0.85% |
| Sales | 0.40B | P/B | 4.15 | EPS next 5Y | 5.92% | ROA | 26.54% | Short Interest | 6.44M | Perf YTD | 19.37% |
| Book/sh | 2.29 | P/C | 6.37 | EPS past 3/5Y | 20.9% 1.58% | ROE | 72.28% | 52W High | -38.18% ($15.35) | Perf Year | 8.71% |
| Cash/sh | 1.49 | P/FCF | 87.05 | Sales past 3/5Y | 72.27% 39.22% | ROIC | 24.26% | 52W Low | 43.35% ($6.62) | Perf 3Y | 113.26% |
| Dividend Est. | - | EV/EBITDA | 4.52 | EPS Y/Y TTM | 136.8% | Gross Margin | 94.9% | Volatility(W/M) | 4.75% 5.1% | Perf 5Y | -55.86% |
| Dividend TTM | - | EV/Sales | 2.22 | Sales Y/Y TTM | 948.35% | Oper. Margin | 45.94% | ATR (14) | 0.53 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.76 | EPS Q/Q | 455.9% | Profit Margin | 19.87% | RSI (14) | 38.33 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.76 | Sales Q/Q | 8608.59% | SMA20 | -4.25% ($9.91) | Beta | 1.08 | Target Price | $27.75 |
| Payout | - | Debt/Eq | 0.52 | Earnings | 2026/8/13 | SMA50 | -18.99% ($11.71) | Rel Volume | 0.56 | Prev Close | $9.7 |
| Employees | 403 | LT Debt/Eq | 0.51 | EPS/Sales Surpr. | 473.12% 45819.14% | SMA200 | -7.95% ($10.31) | Avg Volume(3M) | 0.80M | Price | $9.49 |
| IPO | 2018/6/8 | Option/Short | Yes/Yes | Trades | 5530 | Volume | 452,209 | Change | -2.22% |
🧬 MeiraGTx Holdings (ticker: MGTX) is a vertically integrated, clinical-stage biotechnology company developing gene therapies targeting ophthalmic and central nervous system diseases. The company is distinguished by its adeno-associated virus (AAV) vector-based therapies, its proprietary riboswitch platform for regulating gene expression, and its in-house manufacturing capabilities. It is building a late-stage clinical pipeline aimed at addressing unmet medical needs in rare genetic diseases.
Over the past 1 year, roughly in the middle
38% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
MGTX makes money exceptionally well
Of every $100 in sales, $45.94 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by +121.1% this year.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $452. Peers typically go for $2,000.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -55.9%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 63.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #165 of 597 in the industry
Based on market cap of $911M.
GLUE#162 Monte Rosa Therapeutics Inc $918M PER - 
OBX#163 Obsidian Therapeutics Inc $914M PER 0.1 
KURA#164 Kura Oncology Inc $913M PER - MGTX#165 MeiraGTx Holdings plc $911M PER 13.4 
ALMS#166 Alumis Inc $898M PER - 
FAQ
What kind of company is MGTX?
MGTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of MGTX?
The market cap of MGTX is approximately $911M, ranking 2,639 within its sector.
What is the P/E ratio of MGTX?
MGTX has a P/E ratio of approximately 13.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for MGTX?
MGTX has recorded a 52-week high of $15.35 and a low of $6.62.
